244 related articles for article (PubMed ID: 27440835)
1. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Schernthaner G; Cahn A; Raz I
Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
[No Abstract] [Full Text] [Related]
2. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
3. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
4. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
6. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
7. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
Gallwitz B; Nitschmann S
Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
[No Abstract] [Full Text] [Related]
8. Saxagliptin, alogliptin, and cardiovascular outcomes.
Standl E
N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
[No Abstract] [Full Text] [Related]
9. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
10. New oral hypoglycaemics fail to show cardiovascular benefits.
Cohen D
BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
[No Abstract] [Full Text] [Related]
11. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
Schernthaner G; Sattar N
J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
[No Abstract] [Full Text] [Related]
12. Diabetes: Cardiovascular safety of 'gliptin' therapy.
Lim GB
Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
[No Abstract] [Full Text] [Related]
13. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Greenhill C
Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
[No Abstract] [Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Davis TM
Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
[No Abstract] [Full Text] [Related]
15. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Hirshberg B; Katz A
Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Effects of Incretin-Based Therapies.
White WB; Baker WL
Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
[TBL] [Abstract][Full Text] [Related]
17. An update on the 'gliptins'.
Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
[TBL] [Abstract][Full Text] [Related]
18. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Gwaltney SL
Curr Top Med Chem; 2008; 8(17):1545-52. PubMed ID: 19075765
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria.
Cebrián Cuenca AM; Orozco Beltrán D; Navarro Pérez J; Álvarez-Guisasola F; Núñez Villota J; Consuegra-Sánchez L
Rev Esp Cardiol (Engl Ed); 2017 Dec; 70(12):1143-1144. PubMed ID: 28284632
[No Abstract] [Full Text] [Related]
[Next] [New Search]